Glucose variability and diabetes complication risk: We need to know the answer

Diabetic Medicine

Volumn 27, Issue 8, 2010, Pages 868-871

  Kilpatrick, E S ^a   Rigby, A S ^b   Atkin, S L ^c  

^a HULL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

glucose variability; HbA1c; microvascular complications

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; REACTIVE OXYGEN METABOLITE;

DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; ENDOTHELIAL DYSFUNCTION; HUMAN; IN VITRO STUDY; REVIEW; DIABETIC ANGIOPATHY; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OXIDATIVE STRESS; PHYSIOLOGY; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; OXIDATIVE STRESS; RISK FACTORS;

EID: 77954789710     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.02929.x     Document Type: Review

References (33)

1. Ceriello A, Ihnat M. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 2010 27 : 862 867.
2. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005 54 : 1615 1625.
3. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J-P et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 2006 295 : 1681 1687.
4. Wentholt I, Kulik W, Michels R, Hoekstra J, DeVries J. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008 51 : 183 190.
5. Siegelaar SE, Kulik W, Lenthe Hv, Mukherjee R, Hoekstra JBL, DeVries JH. A randomized clinical trial comparing the effect of basal insulin and inhaled meal-time insulin on glucose variability and oxidative stress. Diabetes Obes Metab 2009 11 : 709 714.
6. 1c affected by glycemic instability? Diabetes Care 2003 26 : 2728 2733.
7. 1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 2006 29 : 352 355.
8. 1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract 2007 77 : 420 426.
9. Koga M, Murai J, Saito H, Kasayama S. Glycated albumin and glycated hemoglobin are differently influenced by endogenous insulin secretion in patients with type 2 diabetes mellitus. Diabetes Care 2010 33 : 270 272.
10. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006 29 : 1486 1490.
11. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001 44 : 1215 1220.
12. Kilpatrick E, Rigby A, Atkin S. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009 32 : 1901.
13. 1c variability and the risk of microvascular complications in type 1 diabetes. Diabetes Care 2008 31 : 2198 2202.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 986.
15. Bragd J, Adamson U, Bäcklund L, Lins P, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008 34 : 612 616.
16. Siegelaar S, Kilpatrick E, Rigby A, Atkin S, Hoekstra J, DeVries J. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009 52 : 2229 2232.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
18. Home P. Contributions of basal and postprandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005 21 : 989 998.
19. 1c. Diabetes Care 2003 26 : 881 885.
20. Pankow J, Kwan D, Duncan B, Schmidt M, Couper D, Golden S et al. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance. Diabetes Care 2007 30 : 325 331.
21. Barr E, Zimmet P, Welborn T, Jolley D, Magliano D, Dunstan D et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007 116 : 151.
22. Raz I, Wilson PWF, Strojek K, Kowalska I, Bozikov V, Gitt AK et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009 32 : 381 386.
23. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 : 2545 2559.
24. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2008 360 : 129 139.
25. Ceriello A. Postprandial hyperglycemia and cardiovascular disease. Diabetes Care 2009 32 : 521 522.
26. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 2653.
27. Holman R, Paul S, Bethel M, Matthews D, Neil H. Ten-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577.
28. 1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 2008 51 : 365 371.
29. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007 50 : 2553 2561.
30. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008 24 : 353 363.
31. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009 360 : 1283 1297.
32. Van den Berghe G, Schetz M, Vlasselaers D, Hermans G, Wilmer A, Bouillon R et al. Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J Clin Endocrinol Metab 2009 94 : 3163 3170.
33. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc 2007 298 : 194 206.